natgillin/translations-raw huggingface dataset:
A process for the preparation of the suspension modifying granulate (II) used in the dosage form according to any of claims 1 to 10 wherein the process comprises the step that the rapidly dissolving diluent and the gelling agent are mixed and granulated together and thereafter dried, resulting in that the rapidly dissolving diluent is randomly distributed in and on the obtained individual granule particles. 
Postupak za dobivanje granulata koji prilagođava suspenziju (II) koji se koristi u obliku doziranja prema bilo kojem od zahtjeva 1 do 10 naznačen time da postupak uključuje korak da su razrjeđivač za brzo otapanje i sredstvo za geliranje pomiješani 1 granulirani zajedno i nakon toga osušeni, što kao rezultat ima da je razrjeđivač za brzo otapanje nasumično raspoređen unutar i na dobivenim pojedinačnim česticama granula.
The compound of claim 5 wherein X is O, Y is O, and q is 0 or 1. 
Spoj u skladu s patentnim zahtjevom 5, naznačen time, da X je O, Yje O, aqje0ili 1.
A developer supply container according to claim 2, wherein said drive converting portion (2d, 3b) converts the rotational force received by said gear portion (2a) to the force for operating said pump portion (2b) in an axial direction of said developer accommodating chamber (2, 2k). 
Spremnik za nadopunjavanje razvijača u skladu s patentnim zahtjevima 14 ili 15, naznačen time što navedeni dio za pretvorbu pogona (2d, 3b) pretvara silu vrtnje na takav način da kada je navedena pregrada (17) u otvorenom položaju, gdje navedeni crpni dio (2b) ne radi.
The antibody or antigen-binding fragment thereof or the composition as claimed in any one of claims 1-15 and 22, for use in the treatment of a disease or disorder associated with over-expression of hGM-CSF in a subject, wherein the antibody or antigen-binding fragment thereof binds hGM-CSF and is capable of neutralizing hGM-CSF activity. 
Protutijelo ili njegov fragment koji se veže na antigen prema jednom od zahtjeva 1 do 13, ili farmaceutski sastav prema zahtjevu 14, naznačen(o) time, da se upotrebljava za liječenje subjekta od bolesti ili poremećaja koji(a) je povezan(a) s prekomjernom ekspresijom hGM-CSF.
The method of claim 1, further comprising before or during fermentation adding to the biomass a material utilizable as a nutrient by any of the microorganisms and/or a material of increased surface area. The method of claim 1, wherein the bacterium culture is applied, relative to the volume of the biomass, in a ratio of 5 to 20 v/v %. 
Primjena bilo kojeg od zahtjeva 1 do 4, naznačena time da se termofilna, anaerobna, acetogena bakterija koja proizvodi vodik koristi zajedno s aditivom, koji je po mogućnosti tvar kojeg bilo koji od mikroorganizama može iskoristiti kao hranjivu tvar i/ili tvar veće površine.
identify an entry affiliated with said target record; permit the retrieval of said at least one set of connected controlled credentials pertaining to said entry and permit the release of said at least one set of connected controlled credentials to said network endpoint, said network endpoint being a permitted recipient of a type of said at least one set of connected controlled credentials. 
dopuštanje preuzimanja navedenog najmanje jednog kompleta povezanih kontroliranih vjerodajnica koji pripada navedenom unosu (103) i dopuštanje puštanja navedenog najmanje jednog kompleta povezanih kontroliranih vjerodajnica u navedenu krajnju točku mreže (110), gdje je navedena krajnja točka mreže dopušteni primatelj tipa navedenog najmanje jednog kompleta povezanih kontroliranih vjerodajnica.
The ability to inhibit Fc epsilon receptor dependent mast cell and basophil responses results in additional anti-inflammatory and anti-allergic activity for the present compounds. 
Sposobnost za inhibiciju odgovora ovisnih o Fc epsilon receptoru kod stanica mastocita i bazofila rezultira u dodatnoj protuupalnoj i protualergijskoj aktivnosti prikazanih spojeva.
A manually adjustable control knob 72 can be adjusted to different settings 74 for control 70 to provide a range of pump speeds (i.e. 
Ručno podesivi kontrolni gumb 72 može se podesiti u različite položaje 72 komande 70 da bi se ostvario opseg brzina pumpe (tj.
A compound according to Formula I, 
Spoj formule I, REHN
The use according to any one of embodiments 1 to 10, wherein the pharmaceutical composition also contains a thrombolytic agent or is for use in combination with a thrombolytic agent or after subsequent treatment with such agent. 
Upotreba u skladu s bilo kojim od patentnih zahtjeva 1-10, naznačena time što farmaceutski pripravak također sadrži trombolitičko sredstvo, ili je namijenjen upotrebi u kombinaciji s trombolitičkim sredstvom, ili je namijenjen upotrebi nakon liječenja s takvim sredstvom.
In one embodiment, the cells are selected from the group consisting of BSC cells, LLC-MK cells, CV-1 cells, COS cells, VERO cells, MDBK cells, MDCK cells, CRFK cells, RAF cells, RK cells, TCMK-1 cells, LLCPK cells, PK15 cells, LLC-RK cells, MDOK cells, BHK-21 cells, CHO cells, NS-1 cells, MRC-5 cells, WI-38 cells, BHK cells, 293 cells, RK cells, chicken embryo cells and other mammalian cells useful for recombinant protein production known in the art. 
Postupak u skladu s patentnim zahtjevom 1 ili 2, naznačen time što su stanice sisavačke stanice, primjerice stanice BSC, stanice LLC-MK, stanice CV-I, stanice COS, stanice VERO, stanice MDBK, stanice MDCK, stanice CRFEK, stanice RAF, stanice RK, stanice TCMK-I, stanice LLCPK, stanice PK15, stanice LLC-RK, stanice MDOK, stanice BHK-21, stanice CHO, stanice NS-1, stanice MRC-5, stanice WI-38, stanice BHK, stanice 293 ili stanice RK.
Method according to any one of previous claims, characterized in that in step a) where the contour data of the veneer planks following natural curvature along with the images of veneer planks are scanned and recorded into the computer database, said data comprising additionally at least the data of the length, width, thickness and contour of the plank, data of the contour of bark, pith, heartwood and wane of the veneer planks and wood defects. 
Postupak prema bilo kojem od prethodnih zahtjeva, naznačen time, da u koraku a) gdje su podaci o rubovima konture prirodno zakrivljenih lamela zajedno s izgledima lamela skenirani i sačuvani u bazi podataka računala, navedeni podaci još sadrže barem podatke o duljini, širini, debljini i rubovima konture daske, informacije o kori, srži, bjeljici 1 lisičavosti lamela, te o oštećenjima drveta.
X is selected from the group consisting of O, S(O)m, and NR3; 
X se bira iz skupine koju čine O, S, SO2, NH i NCH3;
In a variation of the process of the invention, the pre-treatment step comprises a granulation operation a3) carried out after the torrefaction operation a2) and before the grinding operation a4). 
Postupak prema zahtjevu 1, naznačen time da korak predobrade obuhvaća operaciju granulacije a3) koja se provodi nakon operacije torefakcije a2) i prije operacije mljevenja a4).
A denotes unbranched or branched alkyl with 1-10 C-atoms, wherein two adjacent CH- and/or CH2-groups may form a double bond and wherein one or two non-adjacent CH- and/or CH2-groups may be replaced by O-atoms and wherein 1-7 H-atoms may be replaced by F or Cl, 
A označava nerazgranati ili razgranati alkil sa 1-10 C-atoma, pri čemu dvije susjedne CH- i/ili CH2-skupine mogu tvoriti dvostruku vezu i pri čemu jedna ili dvije ne-susjedne CH- i/ili CH>-skupine mogu biti zamijenjene sa O-atomima i pri čemu 1-7 H-atoma može biti zamijenjeno sa F ili CI,
A refrigeration method comprising the step of operating a refrigeration cycle using the composition according to claim 1 . 
Rashladni uređaj koji obuhvaća sastav iz bilo kojeg od zahtjeva 1 – 11.
is selected from the group consisting of C6-10aryl(C1-4)alkyl, pyridinyl(C1-4)alkyl, and furanyl(C1-4)alkyl; wherein C6-10aryl, pyridinyl, and furanyl are optionally substituted with one to three R11 substituents independently selected from the group consisting of C1-3alkoxy; tetrazolyl; carboxy; C1-3alkoxycarbonyl; aminocarbonyl; C1-4alkylaminocarbonyl; C1-3alkylaminocarbonyl; C3-6cycloalkylaminocarbonyl; hydroxy(C1-4)alkylaminocarbonyl; C6-10arylaminocarbonyl wherein C6-10aryl is optionally substituted with carboxy or C1-4alkoxycarbonyl; morpholin-4-ylcarbonyl; cyano; halogen; and trifluoromethoxy; provided that no more than one R11 is C6-10arylaminocarbonyl; R2 is hydrogen or C1-4alkyl; 
C;scikloalkilaminokarbonil; hidroksi(C,.g)alkilaminokarbonil; C4_parilaminokarbonil pri čemu Cg.oaril je proizvoljno supstituiran sa karboksi ili C,ualkoksikarbonil; morfolin-4-ilkarbonil, cijano; halogen; trifluorometoksi; Cygalkoksikarbonil: ili karboksi; uz uvjet da ne više od jedan R"' je Ce qoarilaminokarbonil; je vodik ili C,.4alkil; je jedan do dva supstituenta nezavisno izabrana iz skupine koju čine Crsgalkil, bromo i fenil; pri čemu fenil je proizvoljno supstituiran s jednim do tri supstituenta nezavisno izabrana iz skupine koju čine kloro, fluoro, karboksi, aminokarbonil i cijano; je fenil supstituiran sa jednim do tri supstituenta nezavisno izabrana iz skupine koju čine (Crg)alkil, (Ci13)alkoksi, feniKC;.3)alkoksi, hidroksi, Ci.salkilaminokarbonil i aminokarbonil; uz uvjet da ne više od jedan R"' supstituent je aminokarbonil, C, galkilaminokarbonil, hidroksi ili supstituent koji sadrži fenil; je vodik;
Elastomer product according to according to claim 6 which has a content of closed cells of at least 70% relative to the total volume of cells. 
Elastomerni proizvod prema zahtjevu 7, naznačen time što sadrži zatvorene stanice od najmanje 70% u odnosu na ukupni volumen stanica.
Figure 2 is a schematic side-view according to line II-II of the sanding element from figure 1. 
Slika 2 je shematski prikaz elementa za brušenje iz slike 1 u presjeku II-II, gledan s bočne strane.
reacting the aminooxy group of the oligosaccharide with the at least one carbonyl group of the lysosomal enzyme, 
reakciju prve reaktivne skupine oligosaharida s drugom reaktivnom skupinom aminooksi spoja, te se na taj način priprema oligosaharid koji sadrži aminooksi skupinu.
The system according to claim 1, wherein said characteristic signal pattern to be detected is the beginning of the signal. 
- < navedeni karakterističan oblik signala kojeg treba detektirati je na početku signala.
The method according to claim 1, further comprising: comparing the measured tension value with a threshold value and generating an alarm signal when the measured tension value exceeds the threshold value. 
Postupak u skladu s patentnim zahtjevom 1, naznačen time što također uključuje korak uspoređivanja detektirano vrijednosti napetosti s vrijednošću praga i generiranje signala upozorenja kada navedena detektirana vrijednost prelazi navedenu vrijednost praga.
and R5 independently of one another being selected from the group of H—, fluorine, and methyl; preferably independently of one another being H— or fluorine, more preferably R4 and R5 being H; 
R*i R? su međusobno neovisno odabrani iz skupine koju čine: H-, fluor i metil; xje0,1,2,3ili 4; yje0il 1; ili njegove farmaceutski prihvatljive soli. 4.
However, it is also inactive or significantly less active against certain other mutant forms of KIT, for example the D816V mutation commonly found in systemic mastocytosis. The present invention is based upon research that correlates the treatment of a disease characterized by a mutant form of KIT with an appropriate alternative pharmaceutical therapy based on the alternative's ability to inhibit the mutant KIT. 
PATENTNI ZAHTJEVI L Spoj, naznačen time, da je formule A za uporabu u liječenju KIT ovisnog oboljenja kod pacijenta, a koja obuhvaća: a) identificiranje mutantnog oblika KIT povezanog s KIT ovisnim oboljenjem; te b) primjenu navedenom pacijentu količine spoja A učinkovite za inhibiciju mutantnog KIT.
The pharmaceutical composition of claim 42 further comprising a therapeutically effective amount of a chemotherapeutic agent. 
Farmaceutski sastav prema zahtjevu 42, naznačen time, da nadalje obuhvaća terapeutski učinkovitu količinu kemoterapeutskog sredstva.
In some embodiments, R9 is selected from the group consisting of H, —C1-4 alkyl, carbocyclyl and -heterocyclyl. 
Spoj prema zahtjevu 4, naznačen time da R? je odabran iz skupine koja sadrži H, -C,y alkil, karbociklil, i - heterociklil.
wherein the binder component comprises polyvinyl alcohol; wherein the mixture has a viscosity of from 100 to 50,000 mPa*s (cPs) at 25°C and 
naznačen time, što vezivna komponenta sadrži polivinil alkohol; pri čemu smjesa ima viskozitet od 100 do 50 000 mPa*s (cPs) na 25°C i gdje korak učvršćivanja obuhvaća sušenje pomoću struje plina.
The compounds of the invention can be synthesised according to methods well known in the art of organic chemistry in general and especially in the art of steroid chemistry. 
Spojeve prema ovom izumu može se sintetizirati postupcima dobro poznatim u području organske kemije općenito, a osobito u području kemije steroida.
A pharmaceutical composition for use in prophylaxis and/or treatment of prostate carcinoma, the composition comprising a combination of dimethyl isosorbide and a compound selected from compounds having the following formula: wherein a, b and c respectively denote, independently from each other, a single bond or a double bond, with the proviso that at least one of a, b and c represents a double bond, and with the proviso that if a is single bond and b is double bond R2 is not H; is hydrogen or C1 to C6 alkyl; 
Farmaceutski oblik za uporabu u prevenciji iili liječenju karcinoma prostate, oblik sadrži kombinaciju dimetil izosorbida 1 spoj izabran između spojeva koji imaju sljedeću formulu: gdje a, bi c odgovarajuće označavaju, nezavisno jedan od drugoga, jednostruku vezu ili dvostruku vezu, uz uvjet da barem jedan od a, b i c predstavlja dvostruku vezu, i uz uvjet da ako je a jednostruka veza i b je dvostruka veza, tada R, nije H; R, je vodik ili Ci; do C; alkil;
The apparatus of claim 1, wherein the transponders signal the computer (82) or the PLC to signal the radio receiver. 
Uređaj prema zahtjevu 1, naznačen time da transponderi (80) signaliziraju računalu (82) da signalizira radio prijemniku (502) i/ili da aktivira alarm (86).
The use according to claim 16 or 17, wherein the disease or condition is neuropathic pain or pseudobulbar affect. 
Uporaba u skladu s patentnim zahtjevom 16 ili 17, pri čemu je bolest ili stanje neuropatska bol ili pseudobulbarni afekt.
extrusion to obtain an extruded compound containing said vulcanized crumb rubber, SBS and lubricant, wherein the extrusion takes place at a temperature between 160 and 200 °C. 
- < ekstruzija u svrhu dobivanja ekstrudirane smjese koja sadrži spomenutu vulkaniziranu gumu u mrvicama, SBS i mazivo, pri čemu se ekstruzija obavlja na temperaturi između 160 i 200 *C.
The compounds of embodiment 1 wherein R1 is selected from the group consisting of phenyl(C1-3)alkyl, pyridinyl(C1-3)alkyl, and furanyl(C1-3)alkyl; wherein phenyl, pyridinyl, and furanyl are optionally substituted with one to three R11 substituents independently selected from the group consisting of C1-3alkoxy; tetrazolyl, C3-6cycloalkylaminocarbonyl; hydroxy(C1-4)alkylaminocarbonyl; C6-10arylaminocarbonyl wherein C6-10aryl is optionally substituted with carboxy or C1-4alkoxycarbonyl; morpholin-4-ylcarbonyl; chloro; fluoro; trifluoromethoxy; C1-4alkoxycarbonyl; and carboxy; provided that no more than one R11 is C6-10arylaminocarbonyl. 
Spoj prema zahtjevu 1 naznačen time da R' je izabran iz skupine koju čine feniK(C,3)alkil, piridiniKC,;)alkil, i furani(C,;)alkil; pri čemu fenil, piridinil, i furanil su proizvoljno supstituirani sa jednim do tri R!! supstituenta nezavisno izabrana iz skupine koju čine C,;alkoksi; tetrazolil, C,scikloalkilaminokarbonil; hidroksi(C1.4) alkilaminokarbonil:; Cgsoarilaminokarbonil pri čemu CÂ«,oaril je proizvoljno supstituiran sa karboksi ili Ci4alkoksikarbonilom; morfolin-4-ilkarbonil; kloro; fluoro; trifluorometoksi; Ciaalkoksikarbonil; i karboksi; uz uvjet da ne više od jedan R" je C4.,oarilaminokarbonil.
A composition according to claim 1, which comprises as component (A) the compound 3-difluoromethyl-1-methyl-1H-pyrazole-4-carboxylic acid (9-difluoromethylidene-benzonorbornene-5-yl)amide and as component (B) cyprodinil. 
Pripravak prema zahtjevu 1, naznačen time da je komponenta (A) 3-difluorometil-1-metil-1H-pirazol-4-karboksilna kiselina (9-difluorometiliden-benzonorbornen-5-il)amid i komponenta (B) je odabrana od azoksistrobina i pikoksistrobina.
The drug substance was triturated in a mortar pestle with the respective antioxidant, and then mixed in the dry state with other excipients listed in the following table. 
Ljekovita supstanca je triturirana u avanu sa odgovarajućim antioksidantom, i zatim je miješana u suhom stanju sa drugim inertnim puniteljiima navedenim u slijedećoj tabeli.
A kit for use in treating a TLR8-mediated condition, comprising: 
Komplet namijenjen upotrebi u liječenju stanja kojeg urokuje TLR8, naznačen time što se sastoji od:
The compound of claim 2 wherein R1 is substituted or unsubstituted C1-C6-alkyl or substituted or unsubstituted C2-C6 alkenyl. 
Spoj prema zahtjevu 2 naznačen time da R, je supstituirani ili nesupstituirani C;-Cy-alkil ili supstituirani ili nesupstituirani C2-Cg alkenil.
CARILRGGSGMDL [SEQ ID NO:30] wherein the potency of the antibody or antigen-binding fragment for dendritic cell activation is higher than, or is equal to, its potency for B cell activation and wherein the antibody or antigen-binding fragment has an affinity (KD) for CD40 of less than 1x10-10 M wherein the antibody or an antigen-binding fragment thereof are capable of binding to domain 1 of CD40 and wherein the affinity (KD) for CD40 is measured by surface plasmon resonance. 
CARILRGGSGMDL [SEQ ID NO:30] pri čemu jačina protutijela ili fragmenta vezanja antigena za aktivaciju dendritske stanice je veća od, ili je jednaka s, njegovom snagom za aktivaciju B stanice i pri čemu protutijelo ili fragment za vezanje antigena ima afinitet (KD) za CD40 manji od 1x107" M pri čemu protutijelo ili njegov fragment za vezanje antigena se može vezati za domenu 1 CD40 i pri čemu se afinitet (KD) za CD40 mjeri pomoću rezonancije površinskog plazmona.
a LDPC encoder configured to LDPC-encode the BCH encoded PLP data; 
BCH-kodiranje PLP podatka zbog stvaranja podataka zaštićenih od pogreške;
Use of a pharmaceutical composition according to one of the claims 1 to 7 for the manufacture of a medicament for 
Farmaceutski sastav prema jednom od prethodnih zahtjeva, naznačen time, da sadrži količinu od 0,5 do 10 mg DPP IV-inhibitora.
a fluid actuator coupled to the at least one spray nozzle adapted to spray a specified amount of regeneration fluid in the cylindrical body; 
regulator fluida (135) povezan s najmanje jednom mlaznicom za raspršivanje (131) prilagođen da kada je aktiviran raspršuje određenu količinu regeneracijskog fluida u cilindrično tijelo (110);
The system of claim 1, wherein the SIP Proxy Server is further configured to: 
SIP proksi server sukladno zahtjevu 1, nadalje dizajniran da:
The rigid piston assembly according to claim 1, wherein at least a portion of the disc shaped body of the piston seal is attached to at least a portion of the disc shaped member. 
Sklop krutog klipa prema zahtjevu 2, naznačen time da je mnoštvo kanala (94) zadržnog prstena (90, 290) manje u promjeru nego prolaz postavljen kroz tijelo zaobilaznog uređaja (300).
An engineered DKK-1 antibody according to claim 1, wherein the engineered DKK-1 antibody comprises a light chain comprising the amino acid sequence of SEQ ID NO: 34 and a heavy chain comprising the amino acid sequence of SEQ ID NO: 35. 
Konstruirano protutijelo protiv DKK-1 u skladu s patentnim zahtjevom 1, naznačen time što konstruirano protutijelo protiv DKK-1 sadrži teški lanac, koji ima aminokiselinski slijed SEQ ID NO: 18 i laki lanac, koji ima aminokiselinski slijed SEQ ID NO: 20.
The process of claim 5 wherein the fibrid-containing suspension of step (b) is filtered to isolate the fibrids. 
Postupak u skladu s patentnim zahtjevom 5, pri čemu se suspenzija koja sadrži fibride u skladu s korakom (b) filtrira kako bi se izolirali fibridi.
The analysis cartridge system of paragraph 19 wherein in the breath analysis cartridge the breath chamber is sealed from the fluid chamber when the filter assembly is in the first position, and wherein in the fluorescence analysis cartridge the upper chamber is sealed from the fluid chamber when the filter assembly is in the first position. 
Sustav kazete za analizu prema zahtjevu 8, naznačen time, da je u kazeti za analizu daha komora za dah zabrtvljena prema fluidnoj komori kada je filterski sklop u prvoj poziciji, te time, da je u fluorescentnoj kazeti za analizu gornja komora zabrtvljena prema fluidnoj komori kada je filterski sklop u prvoj poziciji.
The process according to the invention is performed with a total of at least 3 molar equivalents of alkali hypochlorite, organic hypochlorite or at least 2 molar equivalents of alkaline-earth hypochlorite as oxidizing agent; preferably with 3-6 molar equivalents of alkali hypochlorite, or 2-3 molar equivalents of alkaline-earth hypochlorite, especially preferably 3-4 molar equivalents of alkali hypochlorite. 
Ila 20 R i naknadno uklanjanje vode s prikladnom kiselinom da nastane spoj formule IIa; naznačen time da se provodi oksidacija, s najmanje 3 molarna ekvivalenta alkalijskog hipoklorita, organskog hipoklorita ili 2-3 molarna ekvivalenta zemnoalkalijskog hipoklorita kao oksidacijskog sredstva u prisutnosti katalitičkih količina derivata 25
The aqueous phase was washed with dichloromethane (3×150 mL) then the organic phases combined, washed with brine (150 mL), dried (sodium sulfate) and the solvent evaporated. 
Vodenu fazu ispere se diklormetanom (3 x 150 ml), organske faze pomiješa, ispere slanom vodom (150 ml), osuši (natrijev sulfat), a otapalo otpari.
The system as claimed in claim 1 wherein the first electrode (2b.1) has an axially aligned stem having a forward portion having diverging and converging conical portions for self-sealing against an inner insulating sleeve and wherein the first electrode (2b.1) has a bulbous tip. 
Sustav prema zahtjevu 1, pri čemu prva elektroda (2b.1) ima aksijalno centriran štap s prednjim dijelom sa stožastim dijelovima koji se šire i sužavaju te se mogu sami zatvoriti prema unutarnjem rukavu za izolaciju i pri čemu prva elektroda (2b.1) ima ispupčen vrh.
The device according to claim 1 wherein the transmitter, in operation, transmits assignment information indicating the allocated resource blocks to the terminal. 
Integrirani krug sukladno jednom od zahtjeva 1 do 5, naznačen time da su u prvoj dodjeli DVRB-ovi s uzastopnim DVRB brojevima dodijeljeni aparatu mobilnoj stanici.
The image processing apparatus according to any of claims 1 to 4, wherein the image processing apparatus performs image processing so as the isotropic blur image to be subtracted from the band image more largely than the anisotropic blur image when the edge reliability corresponding to the pixel to be processed represents an intermediate value. 
Uređaj za obradu slike prema bilo kojem od zahtjeva 1 do 4, naznačen time, da uređaj za obradu slike izvodi obrađivanje slike tako, što se izotropna zamagljena slika (P1) treba odbiti iz slike na traci (a, B, y) puno opsežnije nego neizotropna zamagljena slika (P2), kako pouzdanost rubova (E) odgovarajuća za piksel koji se treba obraditi, predstavlja srednju vrijednost.
In yet another further example, the formulation also comprises a lubricant, such as magnesium stearate or sodium stearyl fumarate. 
Oralna formulacija u obliku tablete u skladu s patentnim zahtjevom 8, naznačena time što je mazivo 1% do 11%, težinski, magnezijev stearat ili natrijev stearil-fumarat.